In summary, sirolimus is an exciting addition to our immunosuppressive armamentarium. There are encouraging early data suggesting that this drug may have significant advantages over existing agents, namely the promotion of tolerance, reduction in chronic allograft vasculopathy and avoidance of toxic effects of other immunosuppressive drugs. If further large clinical studies can confirm its safety and efficacy over a longer duration of follow-up this will no doubt promote its more widespread adoption.
CITATION STYLE
Dupont, P., & Warrens, A. N. (2003, June 1). The evolving role of sirolimus in renal transplantation. QJM: An International Journal of Medicine. Oxford University Press. https://doi.org/10.1093/qjmed/hcg072
Mendeley helps you to discover research relevant for your work.